(Q40589094)

21 September 2017

title

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks (English)

1 reference

21 September 2017

main subject

phase I clinical trial

0 references

1 reference

M L Rothenberg

1

1 reference

21 September 2017

J G Kuhn

2

1 reference

21 September 2017

L J Schaaf

3

1 reference

21 September 2017

G I Rodriguez

4

1 reference

21 September 2017

S G Eckhardt

5

1 reference

21 September 2017

M A Villalona-Calero

6

1 reference

21 September 2017

D A Rinaldi

7

1 reference

21 September 2017

L A Hammond

8

1 reference

21 September 2017

S Hodges

9

1 reference

21 September 2017

A Sharma

10

1 reference

21 September 2017

G L Elfring

11

1 reference

21 September 2017

R G Petit

12

1 reference

21 September 2017

P K Locker

13

1 reference

21 September 2017

L L Miller

14

1 reference

21 September 2017

D D von Hoff

15

1 reference

21 September 2017

publication date

1 November 2001

1 reference

21 September 2017

1 reference

21 September 2017

volume

12

1 reference

21 September 2017

issue

11

1 reference

21 September 2017

page(s)

1631-1641

1 reference

Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Identification and kinetics of a ?-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

The structural basis of camptothecin interactions with human serum albumin: impact on drug stability

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

CPT-11-induced cholinergic effects in cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

In vitro binding and partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human blood

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1013157727506

7 January 2021

Identifiers

DOI

10.1023/A:1013157727506

1 reference

21 September 2017

1 reference